MARC details
000 -LEADER |
fixed length control field |
04869cam a2200493Ki 4500 |
001 - |
control field |
ocn962411860 |
003 - |
control field |
OCoLC |
005 - |
control field |
20190719103352.0 |
006 - |
fixed length control field |
m o d |
007 - |
fixed length control field |
cr cnu---unuuu |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
161109s2017 enk o 000 0 eng d |
040 ## - |
-- |
IDEBK |
-- |
eng |
-- |
rda |
-- |
pn |
-- |
IDEBK |
-- |
N$T |
-- |
YDX |
-- |
EBLCP |
-- |
NLE |
-- |
OCLCO |
-- |
OPELS |
-- |
N$T |
-- |
OCLCF |
-- |
OCLCQ |
-- |
OTZ |
-- |
IDEBK |
-- |
OCLCQ |
-- |
U3W |
-- |
MERUC |
-- |
D6H |
-- |
YDX |
-- |
OCLCO |
-- |
MERER |
-- |
OCLCQ |
019 ## - |
-- |
962303012 |
-- |
962326192 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9780128028032 |
Qualifying information |
(electronic book) |
|
International Standard Book Number |
0128028033 |
Qualifying information |
(electronic book) |
|
-- |
0128027924 |
|
-- |
9780128027929 |
035 ## - |
-- |
(OCoLC)962411860 |
-- |
(OCoLC)962303012 |
-- |
(OCoLC)962326192 |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
-- |
QP88.2 |
-- |
.M38 2017 |
072 #7 - |
-- |
MED |
-- |
085000 |
-- |
bisacsh |
082 04 - |
Classification number |
617.471 |
-- |
23 |
245 00 - TITLE STATEMENT |
Title |
Materials and devices for bone disorders / |
Statement of responsibility, etc |
edited by Susmita Bose, Amit Bandyopadhyay. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
1 online resource |
505 0# - |
Formatted contents note |
Front Cover; Materials and Devices for Bone Disorders; Copyright Page; Contents; List of Contributors; Biography; Preface; 1 Introduction to Biomaterials and Devices for Bone Disorders; 1.1 Introduction; 1.2 Metallic Biomaterials; 1.3 Ceramic Biomaterials; 1.4 Polymeric Biomaterials; 1.5 Composite Biomaterials; 1.6 Additive Manufacturing (AM) of Biomaterials; 1.7 Biomaterials in Orthopedic Implants Devices; 1.7.1 Joint replacements; 1.7.2 Implants used in osteosynthesis for stabilization and fracture repair; 1.7.3 Spine implants; 1.7.4 Nonconventional implants for bone tumor. |
|
Formatted contents note |
1.7.5 Multifunctional devices1.8 Summary and Future Directions; Acknowledgments; References; 2 Bone Biology and Effects of Pharmaceutical Intervention on Bone Quality; 2.1 Bone Biology; 2.1.1 Bone functions; 2.1.2 Composition; 2.1.3 Architecture; 2.1.4 Bone cells; 2.1.4.1 Osteoclasts; 2.1.4.2 Osteoblast lineage; 2.1.4.2.1 The Wnt-signaling system; 2.1.4.3 Preosteoblasts; 2.1.4.4 Reversal cells; 2.1.4.5 Mature osteoblasts; 2.1.4.6 Lining cells; 2.1.4.7 Osteocytes; 2.1.5 Bone remodeling; 2.1.5.1 The basic multicellular unit; 2.1.5.2 Sequence of bone remodeling; 2.1.5.2.1 Origination. |
|
Formatted contents note |
2.1.5.2.2 Activation2.1.5.2.3 Resorption; 2.1.5.2.4 Reversal; 2.1.5.2.5 Formation; 2.1.5.2.6 Mineralization; 2.1.5.2.7 Reestablishing osteocyte network; 2.1.5.2.8 Quiescence; 2.1.6 Fracture repair; 2.1.6.1 Stress fractures; 2.1.6.2 Complete fractures; 2.1.7 Aspects of bone strength; 2.1.7.1 Bone shape; 2.1.7.2 Bone volume; 2.1.7.3 Mineralization density; 2.1.7.4 Microarchitecture; 2.1.7.5 Collagen structure; 2.1.7.6 Ability to repair damage; 2.1.7.7 Crystal characteristics; 2.1.7.8 Bone marrow; 2.1.7.9 Overall bone strength; 2.2 Pharmaceutical Intervention. |
|
Formatted contents note |
2.2.1 Bone loss with aging or disease2.2.2 Actions of systemic hormones and local cytokines; 2.2.2.1 Estrogen; 2.2.2.2 Glucocorticosteroids; 2.2.2.3 Thyroid; 2.2.2.4 Parathyroid; 2.2.2.5 Calcitonin; 2.2.2.6 1,25 (OH)2-Cholecalciferol (1,25D); 2.2.2.7 Insulin and insulin-like growth factor; 2.2.2.8 Serotonin; 2.2.2.9 Local cytokines; 2.2.3 Calcium supplementation; 2.2.4 Bone formation with osteoporosis medications; 2.2.5 Raloxifene; 2.2.6 Bisphosphonates; 2.2.6.1 Short-term effects; 2.2.6.2 Long-term effects; 2.2.6.3 Fracture healing; 2.2.7 Denosumab; 2.2.8 Teriparatide; 2.2.9 Strontium. |
|
Formatted contents note |
2.2.10 Emerging therapies2.2.10.1 Cathepsin K inhibitors; 2.2.10.2 Romosozumab; 2.2.11 Other medications or substances that affect bone strength; 2.2.11.1 Anticonvulsants; 2.2.11.2 Selective serotonin reuptake inhibitors; 2.2.11.3 Carbonic anhydrase inhibitors; 2.2.11.4 Thiazide diuretics; 2.2.11.5 Rosiglitazone; 2.2.11.6 Bortezomib; 2.2.11.7 Lithium; 2.2.11.8 Elements toxic to the bone; 2.2.11.9 Fluoride; 2.3 Summary; References; 3 Bone Disorders; 3.1 Introduction; 3.2 Metabolic Diseases; 3.2.1 Osteoporosis; 3.2.2 Paget's disease; 3.3 Degenerative Disc Disease; 3.4 Osteoarthritis. |
650 #0 - |
Topical term or geographic name as entry element |
Bones |
|
Topical term or geographic name as entry element |
Bones |
|
Topical term or geographic name as entry element |
MEDICAL |
|
Topical term or geographic name as entry element |
Bones |
|
Topical term or geographic name as entry element |
Bones |
700 1# - |
Personal name |
Bose, Susmita, |
Relator term |
editor. |
|
Personal name |
Bandyopadhyay, Amit, |
Relator term |
editor. |
856 40 - |
Uniform Resource Identifier |
http://www.sciencedirect.com/science/book/9780128027929 |
264 #1 - |
-- |
London, United Kingdom ; |
-- |
San Diego, CA : |
-- |
Academic Press, |
-- |
[2017] |
336 ## - |
-- |
text |
-- |
txt |
-- |
rdacontent |
337 ## - |
-- |
computer |
-- |
c |
-- |
rdamedia |
338 ## - |
-- |
online resource |
-- |
cr |
-- |
rdacarrier |
588 0# - |
-- |
Online resource; title from digital title page (viewed on October 26, 2018). |
650 #0 - |
-- |
Mechanical properties. |
|
-- |
Diseases |
-- |
Treatment. |
|
-- |
Surgery |
-- |
General. |
-- |
bisacsh |
|
-- |
Diseases |
-- |
Treatment. |
-- |
fast |
-- |
(OCoLC)fst00836014 |
|
-- |
Mechanical properties. |
-- |
fast |
-- |
(OCoLC)fst00836023 |
655 #4 - |
-- |
Electronic books. |
776 08 - |
-- |
Print version: |
-- |
Materials and devices for bone disorders. |
-- |
London, United Kingdom ; San Diego, CA : Academic Press, [2017] |
-- |
0128027924 |
-- |
9780128027929 |
-- |
(OCoLC)954535271 |
856 40 - |
-- |
ScienceDirect |